Shots:
- Embecta has entered into a definitive agreement to acquire Owen Mumford, expanding drug-delivery capabilities & strengthening global presence in the chronic care market
- As per the deal, Embecta will acquire Owen Mumford for ~£150M (~$199.9M), incl. £100M (~$133.2M) upfront & up to £50M (~$66.6M) in sales-based milestones tied to Aidaptus, with closing expected in Embecta’s fiscal Q3’26
- Embecta adds the Aidaptus platform, combining patient-centric design with advanced tech in a single form factor & unified assembly, streamlining large-scale manufacturing while reducing changeovers & supply chain complexity
Ref: Embecta| Image: Owen Mumford | Press Release
Related News: Amplifon to Acquire GN Store Nord’s Hearing Business for DKK 17B (~$2.59B)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
